Sign In
Buy ARKG
$33.15
-0.260 (-0.778%)
At Close: Jun 08, 2026
ARKG Leads in 1-Week Returns as Biotech Rebounds
02:32pm, Wednesday, 29'th Jun 2022
Biotech funds began their rebound last week as positive trial data and merger and acquisition news revived the sector. The ARK Genomic Revolution ETF (ARKG) rallied 7.15% over one week, ahead of all
A Comprehensive Guide to Genomic ETFs
05:43pm, Tuesday, 28'th Jun 2022
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
ETFs Winners of S&P 500's Second Best Week in 2022
04:58pm, Monday, 27'th Jun 2022
The S&P 500 advanced more than 3% on Friday, logging back-to-back days of gains and marking its first weekly advance since late May.
Get Exposure to the Genomic Revolution With ARKG
03:15pm, Thursday, 09'th Jun 2022
Ultima Genomics has claimed that its first instrument, the UG100, will sequence a human genome for under $100. The news surprised and perhaps delighted the life sciences community, as the price to seq
An Innovative ETF Opportunity That Taps Into Our Increased Understanding of the Human Genome
07:05pm, Wednesday, 08'th Jun 2022
With a targeted disruptive innovation biotechnology-related exchange traded fund strategy, investors can focus on companies driving change in targeted therapeutics, bioinformatics, CRISPR technology,
Change the DNA of Your Portfolio: Growth Opportunities Through Genomics
07:02pm, Tuesday, 07'th Jun 2022
Thanks to DNA sequencing and the genomic revolution, we could be on the cusp of a brand-new era of healthcare solutions that could extend and enhance the quality of human life. Several key biotech com
Investors Flock to ARKK; Fund Sees $658 Million in May Inflows
02:50pm, Friday, 03'rd Jun 2022
The ARK Innovation ETF (ARKK) took in over half a billion dollars in May inflows. ARK Invest's flagship fund saw $658 million in net inflows in May, bringing the year-to-date net inflows to $1.5 billi
Cathie Wood Is Selling Gene Editing Stocks. Here's Why.
11:45am, Thursday, 02'nd Jun 2022
Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?
Some ARKG Components Could Lead in Genetic Testing
10:44am, Wednesday, 01'st Jun 2022
In the healthcare space, it's often said that an ounce of prevention is worth a pound of cure, and that's undeniably true when it comes to cancer prevention and treatment. A clear avenue for bolsterin
ARKG: Don't Expect Any Favorable Return In Short Or Medium Term
10:06am, Wednesday, 11'th May 2022
ARKG has made a massive reshuffling of its portfolio in the past one year, but that is yet to generate results. ARKG had a steep price fall over the past one month, and had a poor price performance ov
ARK Invest: Attempting The Improbable
09:10am, Friday, 06'th May 2022
Early-stage technology investment returns are likely to be highly positively skewed, underscoring the importance of a small number of contributors in ARK's portfolios. Limiting individual position wei
Ark is Sinking: Can Cathie Wood Bounce Back?
12:21pm, Friday, 29'th Apr 2022
Catherine Wood (Trades, Portfolio) is a growth stock investor who believes disruptive innovation and technology are the keys to great investing returns. Her firm's flagship fund, the Ark Innovation ET
Why Investors Should Consider ETFs That Target Innovation Platforms
05:47pm, Wednesday, 27'th Apr 2022
Investors should keep an eye on innovative platforms-related exchange traded funds to capture tomorrow's growth ideas today. In the recent webcast, Refining Your Innovation Exposure: How to Access Tom
Cathie Wood Snaps Back At Critics, Predicts 50% Annual Returns
05:08pm, Tuesday, 19'th Apr 2022
The ARK CEO remains steadfast in her belief that her exchange-traded funds will outperform again.
In Genomics, Tech Matters
01:16pm, Tuesday, 05'th Apr 2022
Genomics has long been one of the more tech-centric corners of the healthcare space, and that remains the case today. That's a strong indication that disruptive technologies often intersect with and d
